Bionoid Pharma Announces Filing of OTCQB Application to Enhance Market Visibility and Liquidity
-
Dana White Confirms Flight to Washington for Trump Meeting on Press Secretary Role
-
NASA Awards $10B Lunar Contract Framework to SpaceX, Blue Origin
-
Dengue Fever Expands Into High Himalayas as Climate Change Warms Nepal
-
Katy Perry Tells Fans Ex-Husband Russell Brand 'Should Be in Jail' During UK Concert
-
IoT Refrigerator Hacks Disrupt Blood Labs and Supermarkets Across Europe and US
-
South African election results renew debate over identity-based voting
-
Post-election pressures complicate US and Israeli decisions on Iran
-
South African voters report smoother local election but declining IEC trust
-
UN members approve talks on treaty protocol against environmental crime
-
Dolly Parton museum and Nashville hotel open after singer’s death
-
Family-run West Sussex beach café prepares for first winter season
-
George and Amal Clooney attend New York political-comedy reading
-
CT scans reveal health and burial clues from Egypt’s Braided Lady mummy
-
British buyers pay substantial premiums for period-home appearance
-
Oxford faces complaints over lecturer’s classroom attire
-
Thomas Markle released to house arrest after child-abuse-image charge
-
Kyren Wilson and John Higgins reach International Championship snooker final
-
Dawn of War 4 developers chose Adeptus Mechanicus for tactical variety
-
New Zealand and Tonga meet for place in Rugby League World Cup final
-
Italy face unbeaten South Africa in Turin Nations Championship match
-
Reports of unsafe AI-toy responses renew calls for child-safety rules
-
ChatGPT interactive interface feature tested across six custom tools
-
Juneau food network combines difficult supply routes with deep sharing traditions
-
Freshways milk-price cut deepens pressure on UK dairy farms
-
India climbs green-transition ranking after first emissions decline in 25 years
-
Labour and National remain virtually tied as New Zealand vote count advances
-
Trump names Stephen Miller as White House chief of staff after midterm losses
-
The Good Daughter adapts Karin Slaughter thriller with Rose Byrne and Meghann Fahy
-
Restored Albanian tower houses anchor new rural tourism trail
-
Heavy-lift drone evacuates wounded Ukrainian soldier from frontline kill zone
-
Sonia Gandhi reflects on family tragedy and reluctant political career
-
Morrison says West Brom recovered after pressure from successive derby losses
-
Pope Leo begins three-country South American tour in Uruguay
-
Britain considers 2027 state visit for Ukraine’s Zelensky
-
Khawaja says entire Australia camp knew of 2018 ball-tampering plan
Bionoid Pharma Announces Filing of OTCQB Application to Enhance Market Visibility and Liquidity
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) today announced that it has submitted an application to uplist from the OTC Pink to the OTCQB Venture Market.
The application process involves a thorough review by OTC Markets Group, which assesses the company's financials, governance, and disclosures. Upon approval, Bionoid Pharma will be able to utilize the U.S. Securities and Exchange Commission's (SEC) modernized Rule 15c2-11 framework, allowing for enhanced market maker participation through the IDQS system without the traditional 30-day waiting period.
"We are excited to take this significant step toward strengthening our capital markets presence," said Wayne Cockburn, CEO of Bionoid Pharma, Inc. "This anticipated transition is expected to enhance trading efficiency, liquidity, and price discovery, benefiting both institutional and retail investors. By increasing market transparency and accessibility, Bionoid Pharma aims to expand its investor base while reaffirming its position as a leader in the health and wellness sector. We look forward to working closely with OTC Markets throughout this process and will continue to keep our shareholders informed of all material developments."
The listing of Bionoid Pharma's common shares on the OTCQB remains subject to final approval. The company will provide updates as the application process progresses.
About Bionoid Pharma, Inc.
Bionoid Pharma, Inc. is an innovative health and wellness company focused on strategic acquisitions and advanced AI technology to expand its revenue streams and brand presence. The company's proprietary AI Maverick platform is designed to drive customer loyalty, operational excellence, and sustainable growth through AI-driven solutions.
Stay Connected:
Website: BionoidPharma.com
OTC Markets: BINP
X (formerly Twitter): @BionoidPharma
For Investor and Media Inquiries:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and beliefs regarding future developments and their potential impact on the company. Forward-looking statements include, but are not limited to, those related to the OTCQB uplisting application, potential benefits of Rule 15c2-11, expected market maker participation, trading improvements, and operational efficiencies. Actual results may differ due to various risks and uncertainties.
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
S.F.Warren--AMWN